Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

HIV Susceptibility of human antigen-specific CD4 T cells in AIDS pathogenesis and vaccine response.

Hu H, Liu F, Kim J, Ratto-Kim S.

Expert Rev Vaccines. 2016 Jun;15(6):709-17. doi: 10.1586/14760584.2016.1147354. Epub 2016 Feb 17. Review.

2.

Sex and Urbanicity Contribute to Variation in Lymphocyte Distribution across Ugandan Populations.

Naluyima P, Eller LA, Ouma BJ, Kyabaggu D, Kataaha P, Guwatudde D, Kibuuka H, Wabwire-Mangen F, Robb ML, Michael NL, de Souza MS, Sandberg JK, Eller MA.

PLoS One. 2016 Jan 5;11(1):e0146196. doi: 10.1371/journal.pone.0146196. eCollection 2016.

3.

HIV DNA Vaccine: Stepwise Improvements Make a Difference.

Felber BK, Valentin A, Rosati M, Bergamaschi C, Pavlakis GN.

Vaccines (Basel). 2014 May 14;2(2):354-79. doi: 10.3390/vaccines2020354. Review.

4.

Optimization of HIV-1 Envelope DNA Vaccine Candidates within Three Different Animal Models, Guinea Pigs, Rabbits and Cynomolgus Macaques.

Borggren M, Vinner L, Andresen BS, Grevstad B, Repits J, Melchers M, Elvang TL, Sanders RW, Martinon F, Dereuddre-Bosquet N, Bowles EJ, Stewart-Jones G, Biswas P, Scarlatti G, Jansson M, Heyndrickx L, Grand RL, Fomsgaard A.

Vaccines (Basel). 2013 Jul 19;1(3):305-27. doi: 10.3390/vaccines1030305.

5.

Preferential infection of human Ad5-specific CD4 T cells by HIV in Ad5 naturally exposed and recombinant Ad5-HIV vaccinated individuals.

Hu H, Eller MA, Zafar S, Zhou Y, Gu M, Wei Z, Currier JR, Marovich MA, Kibuuka HN, Bailer RT, Koup RA, Robb ML, Michael NL, Kim JH, Ratto-Kim S.

Proc Natl Acad Sci U S A. 2014 Sep 16;111(37):13439-44. doi: 10.1073/pnas.1400446111. Epub 2014 Sep 2.

6.

Timing of plasmid cytokine (IL-2/Ig) administration affects HIV-1 vaccine immunogenicity in HIV-seronegative subjects.

Baden LR, Blattner WA, Morgan C, Huang Y, Defawe OD, Sobieszczyk ME, Kochar N, Tomaras GD, McElrath MJ, Russell N, Brandariz K, Cardinali M, Graham BS, Barouch DH, Dolin R; NIAID HIV Vaccine Trials Network 044 Study Team.

J Infect Dis. 2011 Nov 15;204(10):1541-9. doi: 10.1093/infdis/jir615. Epub 2011 Sep 21.

7.

A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204).

Churchyard GJ, Morgan C, Adams E, Hural J, Graham BS, Moodie Z, Grove D, Gray G, Bekker LG, McElrath MJ, Tomaras GD, Goepfert P, Kalams S, Baden LR, Lally M, Dolin R, Blattner W, Kalichman A, Figueroa JP, Pape J, Schechter M, Defawe O, De Rosa SC, Montefiori DC, Nabel GJ, Corey L, Keefer MC; NIAID HIV Vaccine Trials Network.

PLoS One. 2011;6(8):e21225. doi: 10.1371/journal.pone.0021225. Epub 2011 Aug 3.

8.

Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate.

Currier JR, Ngauy V, de Souza MS, Ratto-Kim S, Cox JH, Polonis VR, Earl P, Moss B, Peel S, Slike B, Sriplienchan S, Thongcharoen P, Paris RM, Robb ML, Kim J, Michael NL, Marovich MA.

PLoS One. 2010 Nov 15;5(11):e13983. doi: 10.1371/journal.pone.0013983.

9.

Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa.

Jaoko W, Karita E, Kayitenkore K, Omosa-Manyonyi G, Allen S, Than S, Adams EM, Graham BS, Koup RA, Bailer RT, Smith C, Dally L, Farah B, Anzala O, Muvunyi CM, Bizimana J, Tarragona-Fiol T, Bergin PJ, Hayes P, Ho M, Loughran K, Komaroff W, Stevens G, Thomson H, Boaz MJ, Cox JH, Schmidt C, Gilmour J, Nabel GJ, Fast P, Bwayo J.

PLoS One. 2010 Sep 21;5(9):e12873. doi: 10.1371/journal.pone.0012873.

10.

Long-lasting humoral and cellular immune responses and mucosal dissemination after intramuscular DNA immunization.

Patel V, Valentin A, Kulkarni V, Rosati M, Bergamaschi C, Jalah R, Alicea C, Minang JT, Trivett MT, Ohlen C, Zhao J, Robert-Guroff M, Khan AS, Draghia-Akli R, Felber BK, Pavlakis GN.

Vaccine. 2010 Jul 5;28(30):4827-36. doi: 10.1016/j.vaccine.2010.04.064. Epub 2010 May 6.

11.

Repeated DNA therapeutic vaccination of chronically SIV-infected macaques provides additional virological benefit.

Valentin A, von Gegerfelt A, Rosati M, Miteloudis G, Alicea C, Bergamaschi C, Jalah R, Patel V, Khan AS, Draghia-Akli R, Pavlakis GN, Felber BK.

Vaccine. 2010 Feb 23;28(8):1962-74. doi: 10.1016/j.vaccine.2009.10.099.

12.

Fc receptor-mediated antiviral antibodies.

Forthal DN, Moog C.

Curr Opin HIV AIDS. 2009 Sep;4(5):388-93. doi: 10.1097/COH.0b013e32832f0a89. Review.

13.

Reference intervals in healthy adult Ugandan blood donors and their impact on conducting international vaccine trials.

Eller LA, Eller MA, Ouma B, Kataaha P, Kyabaggu D, Tumusiime R, Wandege J, Sanya R, Sateren WB, Wabwire-Mangen F, Kibuuka H, Robb ML, Michael NL, de Souza MS.

PLoS One. 2008;3(12):e3919. doi: 10.1371/journal.pone.0003919. Epub 2008 Dec 11.

14.

Phase I study of a herpes simplex virus type 2 (HSV-2) DNA vaccine administered to healthy, HSV-2-seronegative adults by a needle-free injection system.

Cattamanchi A, Posavad CM, Wald A, Baine Y, Moses J, Higgins TJ, Ginsberg R, Ciccarelli R, Corey L, Koelle DM.

Clin Vaccine Immunol. 2008 Nov;15(11):1638-43. doi: 10.1128/CVI.00167-08. Epub 2008 Sep 10.

Supplemental Content

Support Center